TrialGynecologic oncology2020

Phase II trial of bevacizumab and sorafenib in recurrent ovarian cancer patients with or without prior-bevacizumab treatment.

Jung-Min Lee et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.